Scott Clayton

Scott is an associate editor at TSI Network. He is the lead reporter and analyst for Dividend Advisor, Power Growth Investor and Canadian Wealth Advisor and a member of the Investment Planning Committee. Scott began his investment and financial career working with Pat McKeough at The Investment Reporter in the 1980s. Subsequently, he worked at the Financial Post Corporation Service for 10 years. He joined TSI Network in 1998. He is a Bachelor of Economics graduate of York University, and he also has an M.B.A. from the Schulich School of Business.

Posts by the author
The best drug stocks will have an established portfolio of drugs without near-term generic competition, plus a number of other up-and-coming drugs in the pipeline.
Not all of the top paying dividend stocks are worth buying because some dividends are unsustainable
By opening yourself up to elevated risk with these alternatives to building a sound stock portfolio, you set yourself up to become one of the “vulnerable investors” out there
Savvy investors who track upcoming spinoffs position themselves to tap some of the market’s best performers
Rather than relying on stock market predictions, look for share value instead
We think that the best drug company stocks to buy could offer you the same strong appeal that we see for gold stocks. Here’s why we like both.
Molson Coors is the world’s third largest brewer. The company now expects to save a total of $600 million annually when it completes its restructuring by the end of 2019.
The question of when to sell stocks you should focus mostly on the overall quality of the shares you hold
Looking for the top artificial intelligence companies to invest in to boost your portfolio returns? Here’s what to look for—and it’s probably not what you were thinking